[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641889":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":78,"collaborators":10,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":10,"enrollmentInfo":90,"targetDuration":10,"studyType":93,"phases":10,"briefSummary":94,"conditions":95,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1: Participants with Moderate-to-Severe Plaque Psoriasis",null,"Participants with confirmed diagnosis of moderate-to-severe plaque psoriasis who have never been treated with biological treatment before, and receiving guselkumab as per routine clinical practice will be enrolled. Only data available per clinical practice will be collected within this study. The primary data source for this study will be the medical records of each participant.",[13],{"name":14,"affiliation":15,"role":16},"Johnson & Johnson Romania SRL Clinical Trial","Johnson & Johnson Romania SRL","STUDY_DIRECTOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[24,37,46,55,60,69],{"facility":25,"status":26,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Mihaila G. Georgiana - Cabinet Medical Individual Dermatovenerologie","RECRUITING","Bârlad","731139","Romania","RO",{"type":32,"coordinates":33},"Point",[34,35],27.66907,46.23175,{"lat":35,"lon":34},{"facility":38,"status":26,"city":39,"state":10,"zip":40,"country":29,"countryCode":30,"cosmosGeoPoint":41,"geoPoint":45,"contacts":10},"Qualimed SRL","Brasov","500073",{"type":32,"coordinates":42},[43,44],25.60613,45.64861,{"lat":44,"lon":43},{"facility":47,"status":26,"city":48,"state":10,"zip":49,"country":29,"countryCode":30,"cosmosGeoPoint":50,"geoPoint":54,"contacts":10},"Spitalul Clinic Colentina 1","Bucharest","020125",{"type":32,"coordinates":51},[52,53],26.10626,44.43225,{"lat":53,"lon":52},{"facility":56,"status":26,"city":48,"state":10,"zip":49,"country":29,"countryCode":30,"cosmosGeoPoint":57,"geoPoint":59,"contacts":10},"Spitalul Clinic Colentina",{"type":32,"coordinates":58},[52,53],{"lat":53,"lon":52},{"facility":61,"status":26,"city":62,"state":10,"zip":63,"country":29,"countryCode":30,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"Derma Lux SRL","Iași","700126",{"type":32,"coordinates":65},[66,67],27.6,47.16667,{"lat":67,"lon":66},{"facility":70,"status":26,"city":71,"state":10,"zip":72,"country":29,"countryCode":30,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Dr Tirziu Dermato Chirurgie SRL","Timișoara","300188",{"type":32,"coordinates":74},[75,76],21.22571,45.75372,{"lat":76,"lon":75},{"type":79,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100641889","a-study-of-persistence-to-guselkumab-treatment-in-participants-with-moderate-to-severe-plaque-psoriasis-in-romania-100641889",false,"NCT07582783","A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania","Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study","PROGRESS-RO","Inclusion criteria:\n\n* Has a confirmed diagnosis of moderate-to-severe plaque psoriasis\n* Participant must sign an informed consent form allowing source data verification in accordance with local requirements\n* Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments\n* No previous exposure to biological treatment, including guselkumab (bio-naive patient)\n* Intended for the treatment with guselkumab according to the approved indication\n\nExclusion criteria:\n\n* Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC)\n* Is pregnant or lactating\n* Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product.\n* Currently enrolled in another observational study sponsored or managed by a Johnson \\& Johnson company","ALL","18 Years",{"count":91,"type":92},200,"ESTIMATED","OBSERVATIONAL","This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.",[96],"Psoriasis","2026-06-10",{"date":99,"type":100},"2026-06-12","ACTUAL",{"date":102,"type":100},"2026-05-15",{"date":104,"type":92},"2028-11-10",{"name":5,"class":6},6]